Overview

This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy.

Primary Objective

Assess the immunogenicity to COVID-19 vaccination in patients with cancer and/or transplant and cellular therapy (TCT) recipients.

Secondary Objectives

• Evaluate the antibodies response to COVID-19 vaccination in immunocompromised patients.
• Evaluate the T cell response to COVID-19 vaccination in immunocompromised patients.

Exploratory Objectives

• Assess incidence and severity of COVID-19 infections by 6 months following immunization with a SARS CoV-2 vaccine.
• Assess the durability immune response to COVID-19 vaccination.
• Assess the immunogenicity of COVID-19 vaccination in immunocompetent children and adolescents without cancer and have not undergone transplant or received cellular therapy.

Eligibility

Inclusion Criteria:

• Patient receiving care at St. Jude Children's Hospital or Le Bonheur Children's Hospital
• Less than 24 years old at the time of enrollment (Day 0)
• Planning to receive a COVID-19 vaccine as part of clinical care
• Patient is one of the following:
  1. Diagnosed with a Hematological Malignancy (Group A), or
  2. Received a hematopoietic cell transplant or cellular therapy (Group B), or
  3. Diagnosed with a solid tumor malignancy (Group C).
  4. Received a solid organ transplant (Group D), or
  5. Does not have cancer and has not received any type of transplant (Group E)
• Willing and able to provide informed consent

Exclusion Criteria:

• Received a COVID-19 vaccine prior to enrollment (Day 0).